A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
Public ClinicalTrials.gov record NCT05375838. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2, Randomized, Stratified, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1073 (SARS-CoV-2 and Influenza Vaccine) Compared to Co-administered mRNA-1010 (Influenza) and mRNA-1273 (SARS-CoV-2) Vaccines and to mRNA- 1010 Vaccine and mRNA-1273 Vaccine Alone in Healthy Adults 18-75 Years of Age
Study identification
- NCT ID
- NCT05375838
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Enrollment
- 550 participants
Conditions and interventions
Conditions
Interventions
- mRNA-1073 Biological
- mRNA-1010 Biological
- mRNA-1273 Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 12, 2022
- Primary completion
- Dec 28, 2022
- Completion
- Dec 28, 2022
- Last update posted
- Feb 27, 2024
2022
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Centers of America | Hollywood | Florida | 33024 | — |
| AES - DRS - Optimal Research Illinois - Peoria | Peoria | Illinois | 61614 | — |
| Meridian | Sioux City | Iowa | 51106 | — |
| Benchmark Research | Metairie | Louisiana | 70006 | — |
| Meridian | Norfolk | Nebraska | 68701 | — |
| Meridian | Binghamton | New York | 13901 | — |
| Rochester Clinical Research Inc | Rochester | New York | 14609 | — |
| Meridian | Cincinnati | Ohio | 45219 | — |
| Meridian | Cincinnati | Ohio | 45246 | — |
| Benchmark Research | Austin | Texas | 78705 | — |
| Benchmark Research | Fort Worth | Texas | 76135 | — |
| DM Clinical Research - CyFair | Houston | Texas | 77065 | — |
| DM Clinical Research - TCDD | Houston | Texas | 77081 | — |
| J Lewis Research | Salt Lake City | Utah | 84121 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05375838, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2024 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05375838 live on ClinicalTrials.gov.